newsfilter
← Latest News
Business Wire·

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

– New findings demonstrate the significant progression-free survival benefit seen in the intent-to-treat population was also consistent across subgroups – – Results from COSMIC-311 served as basis for Exelixis' recent supplemental New Drug Appl